Published in Cancer Res on July 01, 2003
Concomitant activation of the JAK/STAT, PI3K/AKT, and ERK signaling is involved in leptin-mediated promotion of invasion and migration of hepatocellular carcinoma cells. Cancer Res (2007) 2.50
NVP-BEZ235, a novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, elicits multifaceted antitumor activities in human gliomas. Mol Cancer Ther (2009) 2.31
The PTEN/PI3K pathway governs normal vascular development and tumor angiogenesis. Genes Dev (2005) 2.18
Inhibition of PI3K/mTOR pathways in glioblastoma and implications for combination therapy with temozolomide. Neuro Oncol (2011) 1.42
Leptin promotes the proliferative response and invasiveness in human endometrial cancer cells by activating multiple signal-transduction pathways. Endocr Relat Cancer (2006) 1.41
Abrogation of PIK3CA or PIK3R1 reduces proliferation, migration, and invasion in glioblastoma multiforme cells. Oncotarget (2011) 1.39
The phosphoinositide 3-kinase pathway in human cancer: genetic alterations and therapeutic implications. Curr Genomics (2007) 1.33
Cellular and in vivo activity of a novel PI3K inhibitor, PX-866, against human glioblastoma. Neuro Oncol (2010) 1.27
Thrombospondin-based antiangiogenic therapy. Microvasc Res (2007) 1.26
Tasquinimod (ABR-215050), a quinoline-3-carboxamide anti-angiogenic agent, modulates the expression of thrombospondin-1 in human prostate tumors. Mol Cancer (2010) 1.14
Phase I pharmacokinetic and pharmacodynamic study of the pan-PI3K/mTORC vascular targeted pro-drug SF1126 in patients with advanced solid tumours and B-cell malignancies. Eur J Cancer (2012) 1.11
Antiangiogenic gene therapy of cancer: recent developments. J Transl Med (2004) 1.03
Differential activation of Wnt-β-catenin pathway in triple negative breast cancer increases MMP7 in a PTEN dependent manner. PLoS One (2013) 0.93
MDM2 regulates hypoxic hypoxia-inducible factor 1α stability in an E3 ligase, proteasome, and PTEN-phosphatidylinositol 3-kinase-AKT-dependent manner. J Biol Chem (2014) 0.92
Establishment of prognostic models for astrocytic and oligodendroglial brain tumors with standardized quantification of marker gene expression and clinical variables. Biomark Insights (2010) 0.89
Dietary salt activates an endothelial proline-rich tyrosine kinase 2/c-Src/phosphatidylinositol 3-kinase complex to promote endothelial nitric oxide synthase phosphorylation. Hypertension (2008) 0.89
PI3K/AKT/PTEN Signaling as a Molecular Target in Leukemia Angiogenesis. Adv Hematol (2012) 0.88
Intestinal bleeding from arteriovenous malformations of the small bowel in a patient with Cowden syndrome: report of a case. Surg Today (2012) 0.85
The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention. Cancer Chemother Pharmacol (2010) 0.81
An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo. Cancer Chemother Pharmacol (2013) 0.80
LY294002 potentiates the anti-cancer effect of oxaliplatin for gastric cancer via death receptor pathway. World J Gastroenterol (2011) 0.79
PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression. J Neurooncol (2013) 0.78
Anti-tumor efficacy of BEZ235 is complemented by its anti-angiogenic effects via downregulation of PI3K-mTOR-HIF1alpha signaling in HER2-defined breast cancers. Am J Cancer Res (2016) 0.77
[Phosphoinositide 3-kinase (PI3-K) expression. Tumorigenesis of epithelial carcinoma of the mouth]. Pathologe (2004) 0.77
The prognostic effect of PTEN expression status in colorectal cancer development and evaluation of factors affecting it: miR-21 and promoter methylation. J Biomed Sci (2016) 0.77
Inhibition of transfected PTEN on human colon cancer. World J Gastroenterol (2004) 0.76
Developing a Novel Embryo-Larval Zebrafish Xenograft Assay to Prioritize Human Glioblastoma Therapeutics. Zebrafish (2016) 0.75
Association of high microvessel αvβ3 and low PTEN with poor outcome in stage 3 neuroblastoma: rationale for using first in class dual PI3K/BRD4 inhibitor, SF1126. Oncotarget (2016) 0.75
The PTEN, Mdm2, p53 tumor suppressor-oncoprotein network. Trends Biochem Sci (2002) 2.37
'Pseudopalisading' necrosis in glioblastoma: a familiar morphologic feature that links vascular pathology, hypoxia, and angiogenesis. J Neuropathol Exp Neurol (2006) 2.37
A vascular targeted pan phosphoinositide 3-kinase inhibitor prodrug, SF1126, with antitumor and antiangiogenic activity. Cancer Res (2008) 2.30
Levels of HdmX expression dictate the sensitivity of normal and transformed cells to Nutlin-3. Cancer Res (2006) 2.03
PTEN protects p53 from Mdm2 and sensitizes cancer cells to chemotherapy. J Biol Chem (2001) 1.66
The protein phosphatase activity of PTEN regulates SRC family kinases and controls glioma migration. Cancer Res (2008) 1.63
Phosphorylation of human p53 at serine 46 determines promoter selection and whether apoptosis is attenuated or amplified. J Biol Chem (2005) 1.62
Regulation of XIAP translation and induction by MDM2 following irradiation. Cancer Cell (2009) 1.60
Rap1a null mice have altered myeloid cell functions suggesting distinct roles for the closely related Rap1a and 1b proteins. J Immunol (2007) 1.56
PTEN and p53 are required for hypoxia induced expression of maspin in glioblastoma cells. Cell Cycle (2009) 1.54
TGF-beta1-induced expression of human Mdm2 correlates with late-stage metastatic breast cancer. J Clin Invest (2009) 1.50
Mechanisms of disease: the PI3K-Akt-PTEN signaling node--an intercept point for the control of angiogenesis in brain tumors. Nat Clin Pract Neurol (2007) 1.44
Cell type-specific expression of the IkappaB kinases determines the significance of phosphatidylinositol 3-kinase/Akt signaling to NF-kappa B activation. J Biol Chem (2003) 1.37
Delayed activation of insulin-like growth factor-1 receptor/Src/MAPK/Egr-1 signaling regulates clusterin expression, a pro-survival factor. J Biol Chem (2005) 1.36
Ribosomal protein S3: A multi-functional protein that interacts with both p53 and MDM2 through its KH domain. DNA Repair (Amst) (2009) 1.35
Role of glutamine depletion in directing tissue-specific nutrient stress responses to L-asparaginase. J Biol Chem (2006) 1.29
PTEN and hypoxia regulate tissue factor expression and plasma coagulation by glioblastoma. Cancer Res (2005) 1.28
Type 1 TNF receptor forms a complex with and uses Jak2 and c-Src to selectively engage signaling pathways that regulate transcription factor activity. J Immunol (2008) 1.24
Epidermal growth factor receptor and PTEN modulate tissue factor expression in glioblastoma through JunD/activator protein-1 transcriptional activity. Cancer Res (2009) 1.22
Nutlin3 blocks vascular endothelial growth factor induction by preventing the interaction between hypoxia inducible factor 1alpha and Hdm2. Cancer Res (2007) 1.18
Autophagy induction with RAD001 enhances chemosensitivity and radiosensitivity through Met inhibition in papillary thyroid cancer. Mol Cancer Res (2010) 1.18
Akt regulates basal and induced processing of NF-kappaB2 (p100) to p52. J Biol Chem (2006) 1.18
Expression of human papillomavirus type 16 E6 and E7 oncoproteins in primary foreskin keratinocytes is sufficient to alter the expression of angiogenic factors. Oncogene (2004) 1.16
Tissue transglutaminase regulates matrix metalloproteinase-2 in ovarian cancer by modulating cAMP-response element-binding protein activity. J Biol Chem (2009) 1.14
Early growth response gene-1 regulates hypoxia-induced expression of tissue factor in glioblastoma multiforme through hypoxia-inducible factor-1-independent mechanisms. Cancer Res (2006) 1.13
Molecular basis for a direct interaction between the Syk protein-tyrosine kinase and phosphoinositide 3-kinase. J Biol Chem (2004) 1.13
The platelet-derived growth factor receptor alpha is destabilized by geldanamycins in cancer cells. J Biol Chem (2006) 1.13
Inauhzin and Nutlin3 synergistically activate p53 and suppress tumor growth. Cancer Biol Ther (2012) 1.09
Hdm2 nuclear export, regulated by insulin-like growth factor-I/MAPK/p90Rsk signaling, mediates the transformation of human cells. J Biol Chem (2006) 1.08
Heterozygosity for Pten promotes tumorigenesis in a mouse model of medulloblastoma. PLoS One (2010) 1.06
Ceramide signaling in fenretinide-induced endothelial cell apoptosis. J Biol Chem (2002) 1.05
Tumor necrosis factor activates CRE-binding protein through a p38 MAPK/MSK1 signaling pathway in endothelial cells. Am J Physiol Cell Physiol (2004) 1.05
SHP-1 regulates Fcgamma receptor-mediated phagocytosis and the activation of RAC. Blood (2002) 1.04
PHA665752, a small-molecule inhibitor of c-Met, inhibits hepatocyte growth factor-stimulated migration and proliferation of c-Met-positive neuroblastoma cells. BMC Cancer (2009) 1.03
Rac2 specificity in macrophage integrin signaling: potential role for Syk kinase. J Biol Chem (2003) 1.01
In vitro evaluation of pan-PI3-kinase inhibitor SF1126 in trastuzumab-sensitive and trastuzumab-resistant HER2-over-expressing breast cancer cells. Cancer Chemother Pharmacol (2009) 1.00
CYP3A4 mediates growth of estrogen receptor-positive breast cancer cells in part by inducing nuclear translocation of phospho-Stat3 through biosynthesis of (±)-14,15-epoxyeicosatrienoic acid (EET). J Biol Chem (2011) 1.00
CSK controls retinoic acid receptor (RAR) signaling: a RAR-c-SRC signaling axis is required for neuritogenic differentiation. Mol Cell Biol (2007) 0.96
Galectin-3 regulates apoptosis and doxorubicin chemoresistance in papillary thyroid cancer cells. Biochem Biophys Res Commun (2009) 0.96
Autophagy: a new target for advanced papillary thyroid cancer therapy. Surgery (2009) 0.95
Expression and endocytosis of VEGF and its receptors in human colonic vascular endothelial cells. Am J Physiol Gastrointest Liver Physiol (2002) 0.95
Humanized bone marrow mouse model as a preclinical tool to assess therapy-mediated hematotoxicity. Clin Cancer Res (2011) 0.94
Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer. Mol Cancer Res (2009) 0.93
Controlling the Mdm2-Mdmx-p53 Circuit. Pharmaceuticals (Basel) (2010) 0.92
Mitogen-inducible gene-6 is a multifunctional adaptor protein with tumor suppressor-like activity in papillary thyroid cancer. J Clin Endocrinol Metab (2010) 0.92
Involvement of the ubiquitin pathway in decreasing Ku70 levels in response to drug-induced apoptosis. Exp Cell Res (2006) 0.91
Megakaryocytes regulate expression of Pyk2 isoforms and caspase-mediated cleavage of actin in osteoblasts. J Biol Chem (2012) 0.90
Inactivation of p53 signaling by p73 or PTEN ablation results in a transformed phenotype that remains susceptible to Nutlin-3 mediated apoptosis. Cell Cycle (2010) 0.89
CSK negatively regulates nerve growth factor induced neural differentiation and augments AKT kinase activity. Exp Cell Res (2005) 0.88
Sall2 is a novel p75NTR-interacting protein that links NGF signalling to cell cycle progression and neurite outgrowth. EMBO J (2009) 0.87
The ETS oncogene family transcription factor FEV identifies serotonin-producing cells in normal and neoplastic small intestine. Endocr Relat Cancer (2010) 0.87
c-Abl phosphorylation of Mdm2 facilitates Mdm2-Mdmx complex formation. J Biol Chem (2010) 0.87
Association of TP53 mutational status and gender with survival after adjuvant treatment for stage III colon cancer: results of CALGB 89803. Clin Cancer Res (2013) 0.86
Mitogen-inducible gene-6 expression correlates with survival and is an independent predictor of recurrence in BRAF(V600E) positive papillary thyroid cancers. Surgery (2008) 0.85
Induction of apoptotic genes by a p73-phosphatase and tensin homolog (p73-PTEN) protein complex in response to genotoxic stress. J Biol Chem (2011) 0.84
Homeodomain transcription factor NKX2.2 functions in immature cells to control enteroendocrine differentiation and is expressed in gastrointestinal neuroendocrine tumors. Endocr Relat Cancer (2008) 0.84
PTEN controls immunoreceptor (immunoreceptor tyrosine-based activation motif) signaling and the activation of Rac. Blood (2002) 0.83
Up-regulation of hepatitis C virus replication and production by inhibition of MEK/ERK signaling. PLoS One (2009) 0.83
Expression of RAC2 in endothelial cells is required for the postnatal neovascular response. Exp Cell Res (2009) 0.83
Temozolomide-mediated DNA methylation in human myeloid precursor cells: differential involvement of intrinsic and extrinsic apoptotic pathways. Clin Cancer Res (2013) 0.81
The PI-3 kinase-Akt-MDM2-survivin signaling axis in high-risk neuroblastoma: a target for PI-3 kinase inhibitor intervention. Cancer Chemother Pharmacol (2010) 0.81
Pyk2 regulates megakaryocyte-induced increases in osteoblast number and bone formation. J Bone Miner Res (2013) 0.81
Pediatric phase II trials of poly-ICLC in the management of newly diagnosed and recurrent brain tumors. J Pediatr Hematol Oncol (2014) 0.80
Pan-PI-3 kinase inhibitor SF1126 shows antitumor and antiangiogenic activity in renal cell carcinoma. Cancer Chemother Pharmacol (2015) 0.80
An integrin-targeted, pan-isoform, phosphoinositide-3 kinase inhibitor, SF1126, has activity against multiple myeloma in vivo. Cancer Chemother Pharmacol (2013) 0.80
Therapeutic considerations for Mdm2: not just a one trick pony. Expert Opin Drug Discov (2008) 0.79
Synthesis and cancer stem cell-based activity of substituted 5-morpholino-7H-thieno[3,2-b]pyran-7-ones designed as next generation PI3K inhibitors. J Med Chem (2013) 0.79
Signaling pathways involved in megakaryocyte-mediated proliferation of osteoblast lineage cells. J Cell Physiol (2015) 0.79
Thyroid-specific knockout of the tumor suppressor mitogen-inducible gene 6 activates epidermal growth factor receptor signaling pathways and suppresses nuclear factor-κB activity. Surgery (2011) 0.79
p53 regulates Btk-dependent B cell proliferation but not differentiation. J Leukoc Biol (2006) 0.79
PTEN status mediates 2ME2 anti-tumor efficacy in preclinical glioblastoma models: role of HIF1α suppression. J Neurooncol (2013) 0.78
Serdemetan antagonizes the Mdm2-HIF1α axis leading to decreased levels of glycolytic enzymes. PLoS One (2013) 0.77
Integration of DNA damage and repair with murine double-minute 2 (Mdm2) in tumorigenesis. Int J Mol Sci (2012) 0.76
The Sall2 transcription factor is a novel p75NTR binding protein that promotes the development and function of neurons. Ann N Y Acad Sci (2008) 0.76
Lack of NKX2.2 expression in bronchopulmonary typical carcinoid tumors: implications for patients with neuroendocrine tumor metastases and unknown primary site. J Surg Res (2010) 0.75